Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy

Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibr...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in hematology 2020, Vol.2020 (2020), p.1-5
Main Authors: Stagg, M. Patrick, McCarty, Dillon K., Hughes, John H., Miatech, Jennifer L.
Format: Article
Language:English
Subjects:
Anemia
Anticoagulants
Anticoagulants (Medicine)
Aspirin
B cells
Blood platelets
Blood tests
Bone marrow
Cancer
Cardiac arrhythmia
Cardiac tamponade
Care and treatment
Case Report
Case reports
Esophagus
Glycoproteins
Heart rate
Hemoglobin
Hemorrhage
Infections
Laboratories
Leukemia
Lymphocytes
Pain
Pantoprazole
Patients
Phosphatase
Signal transduction
Targeted cancer therapy
Tumors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibrutinib is thought to be related to its effect on several platelet signaling pathways, which can be exacerbated in the setting of concurrent antiplatelet or anticoagulant therapy. We present an 82-year-old male with CLL on ibrutinib and concurrent antiplatelet therapy who developed cardiac tamponade due to a hemorrhagic pericardial effusion requiring emergent placement of a pericardial window. This case further highlights the risk of major bleeding in patients treated with ibrutinib and concurrent antiplatelet therapy.
ISSN:2090-6560
2090-6579
DOI:10.1155/2020/4282486